DYAI Share Price Performance

US$0.94

0.00 (0.05%)

US$6.00

Fair Value

US$0.94

0.00 (0.05%)

84.3% undervalued

US$6.00

Fair Value

US$0.94

US$6.00

US$9.00

US$5.00

Tue, 23 Jun 26

Fair ValueUS$6.00

Share Pricen/a

DYAI Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value US$6 84.3% undervalued

Analysts Weigh New Risks and Opportunities as Dyadic International Faces Lower Growth Projections

AnalystHighTarget's

Fair Value

Fair Value US$9 89.6% undervalued

Animal Free Protein Platforms And Partnerships Will Transform Long Term Earnings Quality

AnalystLowTarget's

Fair Value

Fair Value US$5 81.2% undervalued

Animal Free Enzymes And Proteins Will Face Delays Yet Ultimately Unlock Long-Term Potential

About DYAI

Founded: 1979
Employees: 5
CEO: Mark Emalfarb
WebsiteView website: www.dyadic.com

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Recent DYAI News & Updates

Announcement • Jun 20

Dyadic International, Inc. Receives Notification from Nasdaq Regarding Delisting of Common Stock

On June 18, 2026, Dyadic International, Inc. received a notification from The Nasdaq Stock Market LLC informing the Company that Nasdaq has initiated a process that could result in the delisting of the Company's securities from Nasdaq due to the Company's failure to comply with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule"), which requires listed companies to maintain a minimum bid price of $1.00 per share. As previously disclosed, in accordance with the Bid Price Rule, the Company was provided 180 calendar days, or until June 17, 2026, to regain compliance with the Bid Price Rule. The Company would be eligible for an additional 180 calendar days (until December 15, 2026) to cure the deficiency under the Bid Price Rule if it achieved, among other things, the applicable market value of publicly held shares requirement for continued listing and applicable standards for initial listing on the Nasdaq Capital Market, including shareholders' equity of $5 million. As of June 17, 2026, the Company had neither regained compliance with the Bid Price Rule nor met the condition for an extension by having shareholders' equity of at least $5 million. The Notification also cites the Company's failure to comply with the separate Nasdaq Listing Rule 5550(b), which requires it to meet any of the following minimum conditions: $2.5 million in shareholders' equity; $35 million in market value of listed securities; or $500,000 of net income from continuing operations (the Continued Listing Standards"). As previously disclosed, the Company initially had until September 23, 2026 to regain compliance with the Continuing Listing Standards. However, given that the Company is now subject to delisting proceedings for the Bid Price Rule deficiency, its Continued Listing Standards deficiency serves as an additional basis for delisting of the Company's securities from The Nasdaq Stock Market. In response to the above, the Company plans to request a hearing before an independent Nasdaq hearings panel (the Panel"). The hearing request automatically stays any suspension or delisting action at least through the date of the written panel decision. The Company may determine to take steps to cure the deficiencies under the Bid Price Rule and the Continuing Listing Standards prior to the date of the hearing by the Panel. To the extent the Company does not or is unable to take those steps, or the Panel determines to hear the Company's matter regardless of any cure by the Company prior to the hearing date, the Company may determine to seek at the Panel, subject to the Panel's discretion, an extension to regain compliance with the Bid Price Rule and the Continued Listing Standards. Pursuant to the relevant Nasdaq Listing Rules, the maximum amount of time that can be granted by the Panel for compliance with the Bid Price Rule and Continuing Listing Standards runs through December 15, 2026. Despite the efforts described above, there can be no assurance that the Company will ultimately regain compliance with all applicable requirements for continued listing, that the Panel will grant the Company a further extension to the extent requested by the Company, or that the Panel will determine to avoid delisting the Company following any cure of the relevant deficiencies. An adverse Panel decision may also be eligible for a further appeal to the Nasdaq Listing and Hearing Review Council. For more information on the delisting process and the consequences of any adverse determination by the Panel, see If we fail to comply with listing standards of the Nasdaq Stock Market LLC (Nasdaq"), our common stock may be delisted, adversely affecting the liquidity and market price of our common stock, as well as our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern." in Part I, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission on March 25, 2026, as amended on April 30, 2026.

Recent updates

No updates

Dyadic International, Inc. Stock Price

DYAI Share Price Performance

DYAI Community Narratives

Analysts Weigh New Risks and Opportunities as Dyadic International Faces Lower Growth Projections

Animal Free Protein Platforms And Partnerships Will Transform Long Term Earnings Quality

Animal Free Enzymes And Proteins Will Face Delays Yet Ultimately Unlock Long-Term Potential

Analysts Weigh New Risks and Opportunities as Dyadic International Faces Lower Growth Projections

Animal Free Protein Platforms And Partnerships Will Transform Long Term Earnings Quality

Animal Free Enzymes And Proteins Will Face Delays Yet Ultimately Unlock Long-Term Potential

Trending Discussion

Recently Updated Narratives

DYAI: Infectious Disease Collaborations Will Drive Future Upside Despite Nasdaq Delisting Risk

Animal Free Protein Platforms And Partnerships Will Transform Long Term Earnings Quality

Animal Free Enzymes And Proteins Will Face Delays Yet Ultimately Unlock Long-Term Potential

Snowflake Analysis

Dyadic International, Inc. Key Details

About DYAI

Recent DYAI News & Updates

DYAI: Infectious Disease Collaborations Will Drive Future Upside Despite Nasdaq Delisting Risk

Dyadic International, Inc. Receives Notification from Nasdaq Regarding Delisting of Common Stock

DYAI: C1 Platform Collaborations And OEM Enzyme Deals Will Drive Upside

Recent updates

Dyadic International, Inc. Competitors

MAIA Biotechnology

Gain Therapeutics

Rapid Micro Biosystems

iBio